Executive Profile

John C. Reed M.D., Ph.D. Head of Pharma Research & Early Development, Roche Holding AG

Age	Total Calculated Compensation	This person is connected to 5 Board Members in 5 different organizations across 9 different industries. See Board Relationships
54	--

Background

Dr. John C. Reed, M.D, Ph.D has been the Head of Pharma Research & Early Development at Roche Holding AG since April 2, 2013. Dr. Reed has been the President and Chief Executive Officer of Burnham Institute for Medical Research since January 2002. Dr. Reed co-founded IDUN Pharmaceuticals Inc., in 1993. He has served as an Advisor and Consultant to Berlex Laboratories Inc., DAKO Inc., Genta Inc., PharMingen Inc., Rigel Pharmaceuticals Inc., Stratagene Inc., Abbott, Isis ... and other biotechnology and pharmaceutical companies, as well as Robertson Stephens investment bankers. He joined Burnham Institute as Deputy Director of the Cancer Center beginning in 1994, as Scientific Director since 1995, and as Cancer Center Director since 2002 and also served as Director of Oncogene and Tumor Suppressor Gene Program. He has also served in various capacities as an Advisor to the National Cancer Institute, the American Association for Cancer Research (AACR) and American Cancer Society. He has been a Director of Stratagene Corporation since June 2004. He has been Director of Pharmion Corp., since June 2, 2005. He has been a Member of Scientific Advisory Board at Predictive Biosciences, Inc. since May 2007. He serves as a Member of the Scientific Advisory Board at IDUN Pharmaceuticals, Inc. and Guava Technologies Inc. He serves on the board of Directors of Stratagene Inc. and BIOCOM. He also serves as a Member of the Board of Trustees and Member of Scientific Advisory Boardat The Burnham Institute. Dr. Reed served as a Director of ISIS Pharmaceuticals Inc., from February 2002 February 12, 2013. He served as a Director of Repros Therapeutics Inc. from September 29, 2008 to November 1, 2009. He served as a Director of Clovis Oncology, Inc. until February 14, 2013. He served as a Director of IDUN Pharmaceuticals, Inc. He served as a Member of Scientific Advisory Board at Cengent Therapeutics Inc. Dr. Reed is an associate member of UCSD's Cancer Center. From 1989 to 1992, he worked as Assistant Director, Laboratory of Molecular Diagnosis at the hospital of the University of Pennsylvania. He serves as an Assistant Professor, Department of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine. Dr. Reed is an Adjunct professor at the University of California San Diego (UCSD) Department of Molecular Pathology, University of Florida, University of Central Florida, and in San Diego State University's Biology department. His research interests have focused primarily on cancer, but he has also made research contributions for AIDS, autoimmunity, stroke and other diseases. He serves on the Editorial boards of over 12 scientific journals. Dr. Reed is the 2003 recipient of the Bristol-Myers-Squibb unrestricted grant for distinguished cancer research. According to the Institute for Scientific Information, Dr. Reed has published more papers related to apoptosis and has received more citations for his publications than any other scientist in the world. He is the Author of approximately 600 peer-reviewed scientific articles and nearly 75 book chapters. He was also a postdoctoral fellow in molecular biology at the Wistar Institute of Anatomy and Biology. Dr. Reed holds a B.A. in Biochemistry from the University of Virginia and an M.D. in Medicine and a Ph.D. in Immunology from the University of Pennsylvania in 1986, where he also received his clinical and postdoctoral training.

Corporate Headquarters 10901 North Torrey Pines Road La Jolla, California 92037 United States Phone: 858-646-3100 Fax: 858-646-3199 Board Members Memberships Co-founder and Member of Scientific Advisory Board IDUN Pharmaceuticals, Inc. Chief Executive Officer, Director and Member of Advisory Board Sanford-Burnham Medical Research Institute Former Director Clovis Oncology, Inc. 2002-2013 Former Director Isis Pharmaceuticals, Inc. 2004-Present Director, Member of Audit Committee, Member of Compensation Committee and Member of Nominating Committee Stratagene Corporation 2005-Present Independent Director Pharmion LLC 2008-2009 Former Director, Member of Compensation & Option Committee and Member of Nominating & Corporate Governance Committee Repros Therapeutics Inc. Education BA 1980 University of Virginia PhD 1986 University of Pennsylvania MD University of Pennsylvania Other Affiliations IDUN Pharmaceuticals, Inc. Isis Pharmaceuticals, Inc. Cengent Therapeutics Inc. Repros Therapeutics Inc. Pharmion LLC Guava Technologies, Inc. Stratagene Corporation University of Pennsylvania University of Virginia Sanford-Burnham Medical Research Institute University of Pennsylvania - School of Medicine Predictive Biosciences, Inc. Clovis Oncology, Inc.

Annual Compensation There is no Annual Compensation data available. Stocks Options There is no Stock Options data available. Total Compensation There is no Total Compensation data available.

COMPETITOR COMPENSATION

Name	Position/ Company	Compensation
Ian C. Read	Chairman, Chief Executive Officer and Chairman of Executive Committee Pfizer Inc.	$1.7M
Andrew Philip Witty	Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee GlaxoSmithKline plc	$1.9M
Kenneth C. Frazier	Chairman, Chief Executive Officer and President Merck & Co. Inc.	$1.5M
Joseph Jimenez MBA	Chief Executive Officer and Member of Executive Committee Novartis AG	$3.4M
Christopher A. Viehbacher	Chief Executive Officer, Director and Member of Strategy Committee Sanofi	$3.5M
Compensation as of Fiscal Year 2012.